Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine.

Slides:



Advertisements
Similar presentations
Operating on patient with Hepatitis C Sonal Asthana, MD and Norman Kneteman, MD Can J Surg August; 52(4): 337–342. Canadian Journal of Surgery The.
Advertisements

THE PATIENT’S JOURNEY TO TRANSPLANT AND BEYOND
Intermediate stage HCC management
SRTR Transplant Benefit-Based Liver Allocation Robert M. Merion, MD, FACS OPTN/UNOS Liver Forum Atlanta, GA April 12, 2010.
An update on liver transplantation Joint Hospital Surgical Grand Round 19/7/2014.
Teaching Liver cirrhosis with varices. Discussion  Approximately half of patients with cirrhosis have esophageal varices  One-third of all patients.
Hepatitis web study H EPATITIS C C URRICULUM Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah.
CORE Case 2 Workshop Petra Lewis MD Professor of Radiology and OBGYN
Liver pathology: CIRRHOSIS
Why GIVE a Liver Transplant to Patients with GAVE Syndrome
The Recipient Experience Jaime Myers, RN, MSN, CCTC April 29, 2011.
Liver Cirrhosis S. Diana Garcia
PORTAL HYPERTENSION & CHRONIC LIVER DISEASE SEAN CHEN ST GEORGE HEPATOBILIARY & PANCREATIC WORKSHOP 31/05/2014.
1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist.
CIRRHOSIS OF LIVER PORTAL HYPERTENSION HEPATIC ENCHEPALOPATHY
Liver Transplantation Philip Goodney, MD June 22, 2005.
An International Case Study of Lung Transplantation
Clinical Approach to Patients Tanarat Choon-ngarm MD.
Cholestatic liver diseases:
HEPATOCELLULAR CARCINOMA Monton. HCC in Thailand Most common cancer in Thai male Incidence 5 x 100,000 / year Male : female = 3-8:1 Age > 40 yr.
Hepatitis B and Acute Liver Failure Jack Kuritzky, PGY-2 UNC Internal Medicine Morning Report 3/12/10.
Guzman, Alexander Joseph Hipolito, April Lorraine
+ Liver Transplantation for PSC Patients A Transplant Surgeon’s Perspective Tiffany Anthony, MD Annette C. and Harold C. Simmons Transplant Institute Baylor.
Principles of anesthesia in cirrhotic patients
Living Donor Liver Transplantation in PSC Patients Giuliano Testa, MD, FACS, MBA Surgical Director, Living Donor Liver Transplantation Baylor University.
Proposal to Delay the HCC Exception Score Assignment (Resolution 9) Liver and Intestine Committee David Mulligan, Chair November 12 and 13, 2014.
Cirrhosis 18 November 2009 Thomas C Sodeman MD Associate Professor of Medicine Chief, Division of Gastroenterology.
FT in prognostic of HBV FibroTest: predictive value in HBV.
Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.
The Transition to What you need to know for General Surgery/Trauma Date | Presenter Information.
1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.
The Transition to What you need to know for Gastroenterology Date | Presenter Information.
Transjugular Intrahepatic Portosytemic Shunt Kevin A. Smith, MD Interventional Radiologist Roper Radiologists, PA.
Suppressing the Hepatitis C virus, Barriers to Care American Public Health Association APHA 143 rd Annual Meeting&Expo October 31-November 4,2015, Chicago,
Acute On Chronic Liver Failure- Evolution of Concept 23 October 2015.
Dr. Ravi kant Assistant Professor Department of General Medicine.
Liver Seminar for Health Plan Case Managers September 23, 2008 October 2, 2008.
소화기내과 김경엽 Gastroenterology 2011;140:
심 재 준심 재 준 Am J Gastroenterol 2007;102:
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Hashem B. El-Serag,1,2 Eric A. Engels,3 Ola Landgren,3 Elizabeth Chiao,1,2 Louise Henderson,1,2 Harshinie C. Amaratunge,1,2 and Thomas P. Giordano1,2 R1.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
HBV & HCV induced Liver Cirrhosis Iradj Maleki MD Gut & Liver Research Center Mazandaran University of Medical Sciences.
Diagnostic Pathway for Chronic Liver Disease
Hepatocellular Carcinoma: Diagnosis and Management
MELD Score, Listing for Liver Transplant, and Organ Allocation
Liver transplantation and PSC
The Recipient Experience
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Liver Transplantation: 50 years
Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.
Liver Transplant For Patients with PSC
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Changes to HCC Criteria for Auto Approval
Alcoholic liver disease in intensive care
Liver cancer: Approaching a personalized care
Alcoholic Hepatitis (1)
Trends in the management and burden of alcoholic liver disease
Clinical states of cirrhosis and competing risks
Proposal to Delay the HCC Exception Score Assignment
Theresa Hydes, William Gilmore, Nick Sheron, Ian Gilmore 
Calculate Well’s score for PE (BOX1)
Assistant professor of Hepatology Alexandria University
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Management of cirrhosis
Donor Allocation Policy in the US
Liver Transplantation and Organ Allocation in 2019
Proposed algorithm for the management of patients with acute-on-chronic liver failure (ACLF) or decompensated cirrhosis. Proposed algorithm for the management.
Presentation transcript:

Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine

Liver Transplant Evaluation: The Process Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine

Liver Transplant Clinical Indications Decompensated cirrhosis- all causes Hepatocellular carcinoma- defined criteria Acute liver failure Hepatopulmonary Syndrome Portopulmonary Hypertension Metabolic disorders

Liver Transplant  Extrahepatic malignancy  Active infection  Active substance abuse  Cholangiocarcinoma-relative  Significant non-hepatic co- morbidity  Significant portal/SMV thrombosis  Extrahepatic malignancy  Active infection  Active substance abuse  Cholangiocarcinoma-relative  Significant non-hepatic co- morbidity  Significant portal/SMV thrombosis Contraindications LIVER TRANSPLANT – INDICATIONS AND CONTRAINDICATIONS

Cirrhosis Normal Liver Cirrhosis Histopathologic Result of Chronic Liver Diseases

Etiology of Liver Disease

Cirrhosis  End stage of any chronic liver disease  Characterized histologically by regenerative nodules surrounded by fibrous tissue  Clinically there are two types of cirrhosis:  Compensated  Decompensated  End stage of any chronic liver disease  Characterized histologically by regenerative nodules surrounded by fibrous tissue  Clinically there are two types of cirrhosis:  Compensated  Decompensated DEFINITION OF CIRRHOSIS

Compensated cirrhosis Compensated cirrhosis Decompensated cirrhosis Decompensated cirrhosis Death Chronic liver disease Natural History of Chronic Liver Disease Development of complications:  Variceal hemorrhage  Ascites  Encephalopathy  Jaundice  Variceal hemorrhage  Ascites  Encephalopathy  Jaundice NATURAL HISTORY OF CHRONIC LIVER DISEASE

Development of Complications in Compensated Cirrhosis Ascites Jaundice Encephalopathy GI hemorrhage Probability of developing event Months Gines et. al., Hepatology 1987; 7:122 NATURAL HISTORY OF CIRRHOSIS

Months Probability of survival All patients with cirrhosis Decompensated cirrhosis 180 Decompensation Shortens Survival Gines et. al., Hepatology 1987;7:122 Median survival ~ 9 years Median survival ~ 1.6 years SURVIVAL TIMES IN CIRRHOSIS

Liver Transplant  Cirrhosis - all causes (hepatitis C most common indication)  Intrahepatic malignancy  Acute liver failure  Metabolic disease  Cirrhosis - all causes (hepatitis C most common indication)  Intrahepatic malignancy  Acute liver failure  Metabolic disease  Extrahepatic malignancy  Active infection  Active substance abuse  Cholangiocarcinoma  Non hepatic co-morbidity  Extrahepatic malignancy  Active infection  Active substance abuse  Cholangiocarcinoma  Non hepatic co-morbidity Indications Contraindications LIVER TRANSPLANT – INDICATIONS AND CONTRAINDICATIONS

Cirrhosis and Decompensation Compensated cirrhosis patients may be followed for years but once decompensation occurs, liver transplant referral should be done promptly.

Liver Transplant Referral The initial step of the liver transplant referral process is financial clearance. This step requires the designated center to attain financial clearance to begin the evaluation process. It is important to note that neither the patient or the physicians may obtain this clearance. This step may take any where from a few hours up to a few weeks depending on the insurance company.

The Liver Transplant Evaluation Process Once financial clearance is obtained, the liver transplant coordinator will begin communication with the patient. The transplant coordinator is there to review the records, place the orders for the tests, imaging, and consultations needed. This evaluation is usually completed over several days

The Liver Transplant Evaluation Process The patient will have consultations with the following team members during the evaluation: 1. Transplant Financial Counselor 2. Liver Transplant Surgeon 3. Transplant Hepatologist 4. Transplant Social Worker 5. Transplant Dietician 6. Transplant Coordinator 7. Transplant Cardiologist- as needed 8. Other consultants are based on medical indications such as Anesthesia, Pulmonary, Nephrology, Hematolgy/Oncology

Social Worker Evaluation Full assessment of the social support for a patient Development of a suitable 24 hour care plan Evaluation of patient’s financial status to determine if the out of pocket expenses are within the patient’s financial means Assessment of the home including pets: reptiles, birds, cats, chicks/ducklings, exotic pets such as monkeys Alcohol and substance use history including any co-existing psychiatric issues Recommendations for psychiatric evaluation of substance abuse treatment/relapse prevention Functional status of the patient Assess the level of commitment to the transplant process, follow up and compliance Assess for the medical power of attorney, directives to physicians

Medical Review Board The case is then taken to a Medical Review Board It is at this time that the case is fully reviewed with presentations by the primary team members including surgery, hepatology, social worker, dietician, financial counselor. Recommendations from the MRB are made on the needed labs, imaging, and additional consultations are made at this stage

Medical Review Board Patients who appear to be at risk from a financial standpoint will be asked to come up with a financial plan to pay for transplant medications Patients will also be asked to have a 24 hour care plan The social worker evaluation recommendations are reviewed with follow up plans assessed

Liver Transplant Listing Once full clearance is obtained from the medical review board, the patient is then listed for liver transplant using the MELD score determination

MELD Model of End Stage Liver Disease Formula based on bilirubin, INR, creatinine – no subjective component Predicts mortality at 90 days Adopted for liver allocation in Feb 2002 Sickest get transplanted first Avoids certain problems with CTP Accurate in about 80% of patients – requires certain exceptions

MELD Formula ([0.957 x log creat] + [0.378 x log bili] + [1.12 x log INR] ) x 10 Renewed based on score >25 – every 7 days – every 30 days – every 90 days <10 – every year Exceptions: tumors, biliary sepsis, lung diseases, metabolic diseases, bleeding

MELD – Prognostic Significance MELD Score3-Month Mortality (%) < >40100

Months from listing Probability of survival (%) Probability of survival (%) 12 MELD and Survival on Transplant Waiting List MELD AND SURVIVAL ON TRANSPLANT WAITING LIST 33.8% > % 90.7% 92.3% < 15

Share 35 Program This is the newest organ allocation policy. This program requires regional sharing of organs in all patients whose MELD is greater than 35. This program has made a dramatic difference in our abilities to get organs for the sickest patients.

United Network for Organ Sharing (UNOS) Regions UNOS REGIONS

SUMMARY Cirrhosis decompensation such as ascites, encephalopathy, GIB, jaundice should all prompt referral to a liver transplant center Liver transplant assessment is commonly done by the transplant hepatologist with a full evaluation recommended once the MELD score is >15 or if there is a suspected HCC which is within the specified criteria The liver transplant referral process may take days to weeks to complete in the outpatient setting. Urgent inpatient evaluations can be done in 1-2 days. Patients are listed in UNOS based on their MELD scores

Question 1 Which of the following is the most common cause of cirrhosis prompting liver transplant in the U.S.? 1. Alcohol abuse 2. Hepatitis B 3. Hepatitis C 4. Acute Tylenol overdose

Question 2 At what time should a liver transplant evaluation be considered? 1. When the patient first receives the diagnosis of cirrhosis 2. Once the patient deteriorates and is in the ICU 3. When there is evidence of decompensation of the cirrhosis 4. When the crash cart arrives to the bedside

Question 3 When following cirrhosis patients, calculation of the MELD score helps to assess the time at which liver transplant referral should be done. What MELD score has been shown to be the time for transplant referral? 1. MELD < MELD >25 3. MELD >15